Compass Pathways - Magic mushrooms cure even an investor's depression

It was already reported earlier that the 9wk endpoint was indeed reached. The confidence intervals just get really close to each other, that’s what I was squinting at. Plus, the matter wasn’t mentioned separately in this update anymore.

No specific information on that. The CMPS volumes do look like trading is going well, though. Some ADR stocks have very low liquidity.

5 Likes

Thanks for taking the time to dig into this!
In my opinion, when assessing Compass’s FDA approval chances, it’s important to remember that they have chosen a hell of a difficult patient population compared to others. However, that could help in getting payers on board more straightforwardly.
It’s just kind of annoying that investors don’t really seem to grasp this. To me, Definium’s market cap seems to be based on very theoretical TAM estimates from analysts; is anyone actually thinking about the criteria for finding a payer in the foreseeable future, and what the market size really is then? And now people are already worried that Compass has conducted unnecessarily extensive trials, while Definium is running 150-200 patient Phase 3 trials across different indications, and the “gel-haired” types are thinking that the FDA now has a one-Phase-3 policy. Surely one single 150-patient Phase 3 trial can’t be enough for psychedelic therapy, can it?
It’s this Compass conservatism vs. Definium, and in a way, the market is rewarding the “wrong” one. It also comes to mind how these companies communicate follow-up durations. It’s common knowledge that LSD is clearly longer-acting than psilocybin, but even there, Definium somehow managed to present how they’ve devised some 8-point “ready for home” type questionnaire, where they claim the median would be 5.8 hours (whereas Compass has talked about a 6-hour follow-up, which was the study protocol – those Definium patients didn’t actually go home either, even if they filled out a form).
It’s basically that things can be marketed in a way that’s palatable to investors – Definium has a 6 billion market cap even though only one small Phase 3 has been read out…

5 Likes

Psychedelic Alpha has an interesting leak/”insider rumor” regarding the sector company AtaiBeckley. The original leak to Bloomberg was in March, and it seems to be heating up now:

” Sources Say AtaiBeckley Deal Close to Completion

In Q1, rumours of a potential partnering deal concerning AtaiBeckley’s lead candidate, BPL-003 (intranasal 5-MeO-DMT for treatment-resistant depression) swirled, as we reported in March.

Since then, it’s been crickets; at least publicly. But people familiar with the matter told Psychedelic Alpha that news should come soon, with a potential announcement this month.

There are three kinds of offer on the table, the sources told us, including a full takeover of the company, codevelopment of BPL-003 alone, and a royalty investment deal. AtaiBeckley’s board is currently weighing these offers, they said.

The dealmaking process may have been buoyed by Definium’s positive market momentum. Indeed, at least one pharma player came to the table right after the LSD drug developer’s Phase 3 readout, we understand.”

In my estimation, Psychedelic Alpha is a reliable and well-networked source of information, and I look forward to seeing what comes of it. Yesterday, at the opening, I moved my adjusted funds back into ATAI from Compass…

7 Likes

Following the FDA’s communications, it is starting to look like psychedelic drugs are no longer a taboo subject; instead, their entry into the market is being strongly anticipated and prepared for:

The U.S. Food and Drug Administration (FDA or Agency) is issuing this guidance to provide general considerations to sponsors developing psychedelic drugs for the treatment of medical conditions (e.g., psychiatric disorders, substance use disorders).

In recent years, interest in the therapeutic potential of psychedelic drugs has been increasing.

Drug development programs for psychedelic drugs are subject to the same regulations and same evidentiary standards for approval as other drug development programs.

However, designing clinical studies to evaluate the safety and effectiveness of these products presents a number of unique challenges. Psychedelic drugs can cause intense perceptual disturbances and alterations in consciousness that can last for several hours or days.

Some drug development programs incorporate a psychological or behavioral intervention. Investigators hypothesize that psychedelic drugs have both rapid-onset and long-term benefits after only one or a few doses.

These and other unusual characteristics should be considered when designing clinical studies so that the results of those studies can provide reliable data on efficacy and safety.

Next, we are waiting for the final filing to the FDA in Q4 '26, and then 30–60 days from that for the approval decision.

5 Likes

In addition, several other announcements related to psychedelics came from the administration yesterday.

E.g.:
https://www.hhs.gov/press-room/hhs-va-partner-advance-psychedelic-therapies-veterans.html

So, a five-year memorandum of understanding between the VA/HHS regarding psychedelic therapies. Anything that accelerates adoption, which could maximize the benefits of being first to market, is good for Compass.

A summary from Psychedelic Alpha of what was announced yesterday:

” It’s a lot to keep track of, so here’s a simplified list of today’s announcements:

  • FDA issues final guidance for clinical investigations of psychedelics
  • FDA announces September psychedelics public hearing and associated request for comments
  • HHS and VA enter into MOU covering research, clinical development, and potential deployment of psychedelics to veterans
  • FDA and VA enter into MOU covering information sharing and scientific collaboration
  • NIDA awards ibogaine funding
  • ARPA-H announces competitive ibogaine for opioid use disorder funding opportunity
  • HRSA issues RFI pertaining to healthcare infrastructure readiness

For its part, FDA has now set up a dedicated webpage to feature its efforts in this realm. It says that it “has made significant advances in psychedelic drug development”. It’s coming thick and fast, now: three of the four actions it highlights on that webpage were announced today alone.”

(Link to the article: Keeping Up with the Feds: From FDA to HRSA, Washington Backs Psychedelics - Psychedelic Alpha )

4 Likes

The day after tomorrow this might be interesting:

”Neuronetics will participate in a panel discussion titled “Commercializing the Next Wave of Novel Neuropsychiatric Drugs,” alongside Compass Pathways, scheduled for Thursday, July 16, 2026”

https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-participate-panel-discussion-b-riley-securities-mind

I don’t know why this hasn’t been published on Compass’s IR pages?

So, an interventional psychiatry clinic chain that also offers Spravato, and is a partner of Compass, is apparently talking about commercial prospects together with Compass. (I was wondering a few days ago whether this STIM could be a good investment if COMP360 gets approved…)

2 Likes

Any news come out, as both Compass and Definium are up about 10% in after-hours trading?

3 Likes

Could this have an impact? https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-nears-deal-buy-psychedelic-drugmaker-ataibeckley-bloomberg-news-2026-07-15/

4 Likes

Great find @JusaVaan ! The M&A game in psychedelics is now underway:

4 Likes

Great! I believe the purchase price needs to be 4+ billion, i.e., a share price of at least $11; somehow I have a feeling it could even be a bit more. Analysts have just hiked many of their forecasts up to $17.
I was actually thinking a few days ago, when seeing how many acquisitions Eli Lilly has made, whether Lilly could be the rumored suitor. And J&J as the potential partner candidate.
I wouldn’t have guessed that such solid news would come this deep into the middle of the month.
There’s still another company, GHRS, developing the same molecule. So far, acquisitions have been realized with these shorter-acting ones.
I wonder what (Spravato owner) Johnson&Johnson is thinking? One would think they are planning moves now, if not sooner!

Edit: I was wrong about the price. The total deal value is 3.8 billion, of which 2.8 is cash up front (6.75 per share) and 1 billion is in milestone payments (max 2.50 per share). I wonder if this is it, or if someone can still come in and outbid them?

9 Likes

Dr. Guy Goodwin has something to say:

Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy

Key Findings & Qualitative Themes

  • The vast majority (78%) of the administration session was spent in silence.
  • Support was minimal, yet relevant to patients’ feelings of safety and stability. Several participants described the support providers as a reliable and available resource if needed, but largely out of their awareness during treatment.
  • Non-directive support strategies promoted autonomy through the introspective psychedelic state. Participants were empowered to sustain inward focus and self-navigate the treatment without the support provider leading, redirecting or reinterpreting the experience in any way.
  • Primary modes of support included reassurance and validation from physical proximity.

These findings were published in the Journal of Psychopharmacology.

https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Publication-of-Post-Hoc-Analysis-Demonstrating-Distinction-of-COMP360-Trial-Monitoring--Support-from-Psychotherapy/default.aspx

3 Likes

It seems they are starting to highlight PTSD more in their communications.

3 Likes

My initial feelings about the ATAI-Lilly deal were negative. I somehow got the impression that things behind the scenes weren’t as rosy as they seemed, given that ATAI sold at this price, even though the company’s management/Angermayer had previously painted a different picture regarding their goals and the company’s valuation.

The crowd on Reddit and Stocktwits also mostly has bad vibes about the deal, a real “WTF” kind of reaction… Compass also dropped on Thursday on high volume; I thought that was related to the same disappointment regarding the deal’s valuation.

I decided to sell my ATAI position already (and sacrifice the biobucks, as I don’t really believe in the progress of DMT, and the milestones would have practically come from that rather than this BPL-003), and I partially moved more capital into Compass, however, as the current decline seemed to have stopped. I figured that this deal will ultimately be one more thing that brings psychedelics into the news and further validates the sector – and there was a lot of other news last week, too, e.g., from the FDA, and now when you go to the FDA’s homepage, the entire page showcases the FDA’s support for psychedelic research.

At least on Yahoo Finance, the matter is being presented in quite a positive tone.

5 Likes

A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics

https://www.fiercebiotech.com/biotech/rising-tide-scenario-why-other-big-pharmas-could-follow-lilly-psychedelics

3 Likes

It’s interesting that the market doesn’t seem able to bring itself to believe in this scenario. Compass’s stock price didn’t rise after the Atai acquisition, and there doesn’t seem to be any positive momentum in the share price at all. Are psychedelics still considered too uncertain and a niche pharmaceutical sector, or what is that “invisible brake” preventing the stock from rising? :thinking:

3 Likes

This is just a subconscious gut feeling lacking any major factual basis, but I have a nagging fear that Compass might be left with nothing more than the role of a trailblazer and early-stage beneficiary, after which the market entry of short-acting trips could displace Compass as economically unviable, unless data pops up somewhere showing the benefits of a long-acting trip over a short-acting one.

In other words, the market might already be betting on the next mega-hit, the winner of the game, and I don’t know if the one launching the longest treatment time can belong to this group, unless either the data proves the benefits of long treatment duration or the downsides of short ones. Compass is surely trying to prove those benefits, while others are aiming to cover up the weaknesses of the short trip.

In my own reasoning, this would explain why only positive and concrete news related to Compass causes the company’s share price to rise, while the general buzz surrounding psychedelics doesn’t seem to stick to it.

2 Likes

If this were solely about a belief in short-acting [compounds], DFTX couldn’t have jumped to a market cap of 6 billion… because LSD is longer-acting than psilocybin.
So, something else is driving the pressure. Apparently, there were some warrants at a price just under ten; could it be selling pressure related to the ownership/financing structure, such as warrants being converted into shares and then sold? Or is the Usona risk weighing on it? Or perhaps the fact that it’s actually listed in the UK but sold as an ADR (American Depositary Receipt) in the US isn’t attracting larger buyers in the same way?
In my opinion, short-acting ones shouldn’t really hit the market before 2030 (or 2029 at the earliest).
Psilocybin is currently, and for the time being, the most studied of these—academically and within the “industry.” I believe that since doctors are conservative, that’s a good thing until these molecules become more familiar in the future.

3 Likes

I ponder this myself from time to time… there are examples in both directions…

Humira and Remicade. The first-mover advantage lasted, even though, clinically, the drugs are on par with many other TNF-alpha inhibitors. Why? I think anti-inflammatory biological drugs were such a totally new and complex group that clinicians very easily stuck with the first one they became familiar with.

Botox. Successful marketing. Viagra, the same.

Warfarin (Marevan), I don’t know why. Firmly rooted in practice…?

Then, on the other hand, often there is no first-mover advantage, but rather others benefit from the pioneer’s work.

Statins, Opdivo, Ozempic (though Novo made the previous molecules as well), Eylea. These are all, in a way, simpler drugs.

Which category does Psilocybin fall into?

3 Likes

Ugh, yuck, are we really on the same side of a trade as Cathie Wood? It’s better to follow some WSB ape train instead, because Cathie’s track record is nothing special outside of hype stocks. The Shroomstocks comments on the news summarized my reaction perfectly :see_no_evil_monkey:


3 Likes

Well, a hype stock is exactly what we want this to be. Substance seasoned with hype, that’s the best!

2 Likes